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29 314 
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>gb|M15226 | MUSIGLAH H-chain lambda rearranged anti -Dns hybridoma VDJ4 
region of J558 fami1y mRNA. 
1 CAGGTTCAGCTCCAGCAGTCTGGGGCTGAGCTGGCAAGACCTGGGGC‘ITCAGTGAAGTTG 60 
61 TCCTGCAAGGCWCTGGCTACACCTFTACTAGCTACTGGATGCAGTGGGTAAAACAGAGG 120 
121 CCTGGACAGGGTCTGGAATGGATTGGGGCTATTTATCCTGGAGATGGTGATACTAGGTAC 180 
181 ACTCAGAAG'ITCAAGGGCAAGGCCACA‘ITGACTGCAGATAAATCCTCCAGCACAGCCTAC 240 
241 ATGCAACTCAGCAGCTI'GGCATCTGAGGACTCTGCGGTCTATTACTGTGCAAGA 294 
29 317 
318 TGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA 363 
>gblM15225|MUSIGLAG H-chain lambda rearranged anti -Dns hybridoma VDJ4 region 
of J558 famiiy mRNA. 
1 CAGGTTCAGCTCCAGCAGTCTGGGGCTGAGCTGGCAAGACCTGGGGCTTCAGTGAAGTTG 60 
61 TCCTGCAAGGC‘ITCTGGCTACACCT‘ITACTAGCTACTGGATGCAGTGGGTAAAACAGAGG 120 
121 CCTGGACAGGGTCTGGAATGGAWGGGGCTATITATCCTGGAGATGGTGATACTAGGTAC 180 
181 ACTCAGAAGTTCAAGGGCAAGGCCACA'ITGACTGCAGATAAATCCTCCAGCACAGCCTAC 240 
241 ATGCAACTCAGCAGCWGGCATCTGAGGACTCTGCGGTCTATI'ACTGTGCAAGA 294 
295 - - - - - - - - - - - - - - - - - 311 
312 TGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA 357 
>gb|M20835|MUSIGKCLP Mouse IgMk rearranged heavy-chain mRNA variabie region 
(V-D-J) anti -DNA autoantibody. 
106 CAGGTCCAACTGCAGCAGCCTGGTGCTGAGCWGTGAAGCCTGGGGCCTCAGTGAAGCTG 165 
166 TCCTGCAAGGCTTCTGGCTACACTITCACCAGCTACTGGATAAACTGGGTGAAGCAGAGG 225 
226 CCTGGACAAGGCCTTGAGTGGATI'GGAAATATFTATCCTGGTAGTAGTAGTACTAACTAC 285 
286 AATGAGAAGTFCAAGAGCAAGGCCACACTGACTGTAGACACATCCTCCAGCACAGCCTAC 345 
346 ATGCAGCTCAGCAGCCTGACATCTGACGACTCTGCGGTCTATTATTGTGCAAGACG 401 
40 16 
417 TGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA 462 
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